

Multidisciplinary team insights on the promise of new and emerging treatment options for patients with HFrEF



Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabeled or unapproved use*
- *No endorsement by USF Health or touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health or touchIME activities*
- *USF Health and touchIME accept no responsibility for errors or omissions*

Expert panel



Prof. Ahmet Fuat
Carmel Medical Practice,
Darlington and Primary Care
Network, Darlington, UK
Durham University, Durham,
UK



Dr Akshay Desai
Cardiovascular Division,
Brigham and Women's
Hospital, Boston, MA, USA





Dr Carol Wade
University of Maryland Medical
Center, Baltimore, MD, USA



Ms Sarah Worsnop
Hull, UK

Pharmacological management of HFrEF (LVEF ≤40%)



* LVEF ≤35% and patients in sinus rhythm only.

ACC, American College of Cardiology; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor;

ESC, European Society of Cardiology; HFrEF, heart failure with reduced ejection fraction; IDN, isosorbide dinitrate; I_f-channel, funny channel;

LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; sGC, soluble guanylate cyclase; SGLT2i, sodium-glucose cotransporter 2 inhibitor.

1. McDonagh TA, et al. *Eur Heart J.* 2021;42:35993726; 2. Yancy CW, et al. *J Am Coll Cardiol.* 2018;71:201–30; 3. Maddox TM, et al. *J Am Coll Cardiol.* 2021;77:772–810.